Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Discordances between clinical and ultrasound measurements of disease activity among RA patients followed in real life.

Zufferey P, Courvoisier DS, Nissen MJ, Möller B, Brulhart L, Ziswiler HR, Tamborrini G, Ciurea A, D'Agostino MA, Finckh A.

Joint Bone Spine. 2019 Sep 23. pii: S1297-319X(19)30140-X. doi: 10.1016/j.jbspin.2019.09.010. [Epub ahead of print]

PMID:
31557525
2.

Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.

Ørnbjerg LM, Brahe CH, Askling J, Ciurea A, Mann H, Onen F, Kristianslund EK, Nordström D, Santos MJ, Codreanu C, Gómez-Reino J, Rotar Z, Gudbjornsson B, Di Giuseppe D, Nissen MJ, Pavelka K, Birlik M, Kvien T, Eklund KK, Barcelos A, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson ÁJ, Loft AG, van der Horst-Bruinsma I, Jones G, Iannone F, Hyldstrup L, Krogh NS, Hetland ML, Østergaard M.

Ann Rheum Dis. 2019 Nov;78(11):1536-1544. doi: 10.1136/annrheumdis-2019-215427. Epub 2019 Aug 20.

PMID:
31431486
3.

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.

Boel A, Molto A, van der Heijde D, Ciurea A, Dougados M, Gensler LS, Santos MJ, De Miguel E, Poddubnyy D, Rudwaleit M, van Tubergen A, van Gaalen FA, Ramiro S.

Ann Rheum Dis. 2019 Nov;78(11):1545-1549. doi: 10.1136/annrheumdis-2019-215707. Epub 2019 Jul 30.

4.

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis.

Hebeisen M, Scherer A, Micheroli R, Nissen MJ, Tamborrini G, Möller B, Zufferey P, Exer P, Ciurea A.

PLoS One. 2019 May 30;14(5):e0216746. doi: 10.1371/journal.pone.0216746. eCollection 2019.

5.

The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort.

Hiller A, Biedermann L, Fournier N, Butter M, Vavricka SR, Ciurea A, Rogler G, Scharl M; Swiss IBD Cohort Study Group.

PLoS One. 2019 Apr 30;14(4):e0211554. doi: 10.1371/journal.pone.0211554. eCollection 2019.

6.

Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides.

Neidhart M, Pajak A, Laskari K, Riksen NP, Joosten LAB, Netea MG, Lutgens E, Stroes ESG, Ciurea A, Distler O, Grigorian M, Karouzakis E.

Front Immunol. 2019 Apr 15;10:791. doi: 10.3389/fimmu.2019.00791. eCollection 2019.

7.

Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study.

Bühler S, Jaeger VK, Adler S, Bannert B, Brümmerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Müller R, Nissen MJ, Siegrist CA, Villiger PM, Walker UA, Hatz C.

Rheumatology (Oxford). 2019 Sep 1;58(9):1585-1596. doi: 10.1093/rheumatology/kez045.

PMID:
30877773
8.

[Therapy of Psoriasis Arthritis Taking into Account New Treatment Options].

Ryser C, Ciurea A.

Praxis (Bern 1994). 2018;107(21):1147-1153. doi: 10.1024/1661-8157/a003090. Review. German.

PMID:
30326810
9.

Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis.

Cecchinato V, D'Agostino G, Raeli L, Nerviani A, Schiraldi M, Danelon G, Manzo A, Thelen M, Ciurea A, Bianchi ME, Rubartelli A, Pitzalis C, Uguccioni M.

Front Immunol. 2018 Sep 19;9:2118. doi: 10.3389/fimmu.2018.02118. eCollection 2018.

10.

Evaluating the bromodomain protein BRD1 as a therapeutic target in rheumatoid arthritis.

Klein K, Kato M, Frank-Bertoncelj M, Kolling C, Ciurea A, Gay S, Ospelt C.

Sci Rep. 2018 Jul 24;8(1):11125. doi: 10.1038/s41598-018-29127-w.

11.

Barriers and Facilitators of Vigorous Cardiorespiratory Training in Axial Spondyloarthritis: Surveys Among Patients, Physiotherapists, and Rheumatologists.

Niedermann K, Nast I, Ciurea A, Vliet Vlieland T, van Bodegom-Vos L.

Arthritis Care Res (Hoboken). 2019 Jun;71(6):839-851. doi: 10.1002/acr.23705.

PMID:
30004189
12.

[Early undifferentiated arthritis].

Micheroli R, Ciurea A.

Orthopade. 2018 Mar;47(3):261-272. doi: 10.1007/s00132-018-3539-2. Review. German.

PMID:
29468290
13.

Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.

Hebeisen M, Neuenschwander R, Scherer A, Exer P, Weber U, Tamborrini G, Micheroli R, Wildi LM, Zufferey P, Nissen MJ, Villiger PM, Bernhard J, Finckh A, van der Horst-Bruinsma IE, Sieper J, Landewé R, van der Heijde D, Ciurea A; rheumatologists of the Swiss Clinical Quality Management Program.

J Rheumatol. 2018 Apr;45(4):506-512. doi: 10.3899/jrheum.170166. Epub 2018 Feb 15.

PMID:
29449504
14.

Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study.

Zufferey P, Scherer A, Nissen MJ, Ciurea A, Tamborrini G, Brulhart L, Blumhardt S, Toniolo M, Möller B, Ziswiler HR; SONAR Group and the SCQM Foundation.

J Rheumatol. 2018 Jul;45(7):887-894. doi: 10.3899/jrheum.161193. Epub 2018 Jan 15.

PMID:
29335344
15.

TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.

Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewé RBM, van der Heijde D, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.

Ann Rheum Dis. 2018 Jan;77(1):63-69. doi: 10.1136/annrheumdis-2017-211544. Epub 2017 Sep 22.

16.

Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis.

Alpizar-Rodriguez D, Mueller RB, Möller B, Dudler J, Ciurea A, Zufferey P, Kyburz D, Walker UA, von Mühlenen I, Roux-Lombard P, Mahler M, Lamacchia C, Courvoisier DS, Gabay C, Finckh A.

Rheumatology (Oxford). 2017 Sep 1;56(9):1579-1585. doi: 10.1093/rheumatology/kex239.

PMID:
28859327
17.

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.

Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, Möller B, Zufferey P, Nissen MJ, Scherer A, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.

Arthritis Res Ther. 2017 Jul 19;19(1):164. doi: 10.1186/s13075-017-1372-3.

18.

The epigenetic architecture at gene promoters determines cell type-specific LPS tolerance.

Klein K, Frank-Bertoncelj M, Karouzakis E, Gay RE, Kolling C, Ciurea A, Bostanci N, Belibasakis GN, Lin LL, Distler O, Gay S, Ospelt C.

J Autoimmun. 2017 Sep;83:122-133. doi: 10.1016/j.jaut.2017.07.001. Epub 2017 Jul 9.

PMID:
28701277
19.

The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis.

Alpizar-Rodriguez D, Brulhart L, Mueller RB, Möller B, Dudler J, Ciurea A, Walker UA, Von Mühlenen I, Kyburz D, Zufferey P, Mahler M, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen MJ, Courvoisier DS, Gabay C, Finckh A.

Clin Rheumatol. 2017 Mar;36(3):677-682. doi: 10.1007/s10067-017-3547-3. Epub 2017 Jan 21.

PMID:
28110385
20.

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.

van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J.

Ann Rheum Dis. 2017 Jun;76(6):978-991. doi: 10.1136/annrheumdis-2016-210770. Epub 2017 Jan 13. Review.

PMID:
28087505

Supplemental Content

Loading ...
Support Center